When to Resect Following Neoadjuvant Therapy for Esophageal Cancer-issues and Limitations in Addressing This Decision

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2017 Sep 22

PMID 28932595

Citations 1

Authors

Emmanuel Gabriel

Steven N Hochwald

Affiliations

Soon will be listed here.

Citing Articles

Esophageal resection after neoadjuvant therapy: understanding the limitations of large database analyses.

Ranney D, Mulvihill M, Yerokun B, Hartwig M J Thorac Dis. 2017; 9(10):E949-E950.

PMID: 29268443 PMC: 5723804. DOI: 10.21037/jtd.2017.09.13.

References

Gabriel E, Attwood K, Shah R, Nurkin S, Hochwald S, Kukar M . Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma. J Am Coll Surg. 2017; 224(5):884-894.e1. PMC: 5836490. DOI: 10.1016/j.jamcollsurg.2017.01.043. View

Al-Sukhni E, Gabriel E, Attwood K, Kukar M, Nurkin S, Hochwald S . No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. J Am Coll Surg. 2016; 223(6):784-792.e1. DOI: 10.1016/j.jamcollsurg.2016.09.002. View

Lee A, Wong A, Schwartz D, Weiner J, Osborn V, Schreiber D . Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer?. Ann Thorac Surg. 2016; 102(2):433-8. DOI: 10.1016/j.athoracsur.2016.02.058. View

Gabriel E, Attwood K, Du W, Tuttle R, Alnaji R, Nurkin S . Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation. JAMA Surg. 2015; 151(3):234-45. PMC: 5340565. DOI: 10.1001/jamasurg.2015.4068. View

Ranney D, Mulvihill M, Yerokun B, Fitch Z, Sun Z, Yang C . Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?. Eur J Cardiothorac Surg. 2017; 52(3):543-551. DOI: 10.1093/ejcts/ezx132. View

Haisley K, Laird A, Nabavizadeh N, Gatter K, Holland J, Vaccaro G . Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer. JAMA Surg. 2016; 151(11):e162743. DOI: 10.1001/jamasurg.2016.2743. View

Shaikh T, Ruth K, Scott W, Burtness B, Cohen S, Konski A . Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2014; 99(1):270-6. PMC: 4284823. DOI: 10.1016/j.athoracsur.2014.08.033. View

Lin G, Han S, Xu Y, Mao W . Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies. Dis Esophagus. 2015; 29(8):1107-1114. DOI: 10.1111/dote.12432. View

Kim J, Correa A, Vaporciyan A, Roth J, Mehran R, Walsh G . Does the timing of esophagectomy after chemoradiation affect outcome?. Ann Thorac Surg. 2011; 93(1):207-12. PMC: 4041623. DOI: 10.1016/j.athoracsur.2011.05.021. View

10.

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

11.

Tessier W, Gronnier C, Messager M, Hec F, Mirabel X, Robb W . Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer?. Ann Thorac Surg. 2014; 97(4):1181-9. DOI: 10.1016/j.athoracsur.2013.12.026. View